Exact Sciences Corporation (NASDAQ: EXAS) Stock Competitors & Peer Comparison
See EXAS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for EXAS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EXAS | $104.91 | +0.00% | 20B | -95.37 | -$1.10 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.71% |
| TMO | $654.80 | +0.35% | 242.2B | 28.28 | $23.16 | +0.28% |
| DHR | $214.06 | +1.09% | 150.5B | 26.82 | $7.98 | +0.71% |
| NTRA | $410.35 | +0.46% | 58.8B | -310.87 | -$1.32 | N/A |
| A | $167.78 | +0.66% | 47.4B | 28.86 | $5.81 | +0.60% |
| IQV | $258.21 | -0.96% | 42.5B | 21.29 | $12.13 | N/A |
| WAT | $425.21 | -0.08% | 41.7B | 31.08 | $13.68 | N/A |
| ILMN | $273.04 | +2.75% | 41.3B | 54.28 | $5.03 | N/A |
| IDXX | $518.39 | +0.12% | 40.9B | 36.45 | $14.22 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
EXAS vs DHR-PB Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, EXAS's ROE is -0.09%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, EXAS is less volatile compared to DHR-PB. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
EXAS vs TMO Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, TMO has a market cap of 242.2B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while TMO trades at $654.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas TMO's P/E ratio is 28.28. In terms of profitability, EXAS's ROE is -0.09%, compared to TMO's ROE of +0.13%. Regarding short-term risk, EXAS is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
EXAS vs DHR Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, DHR has a market cap of 150.5B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while DHR trades at $214.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas DHR's P/E ratio is 26.82. In terms of profitability, EXAS's ROE is -0.09%, compared to DHR's ROE of +0.08%. Regarding short-term risk, EXAS is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
EXAS vs NTRA Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NTRA has a market cap of 58.8B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while NTRA trades at $410.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NTRA's P/E ratio is -310.87. In terms of profitability, EXAS's ROE is -0.09%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, EXAS is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
EXAS vs A Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, A has a market cap of 47.4B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while A trades at $167.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas A's P/E ratio is 28.86. In terms of profitability, EXAS's ROE is -0.09%, compared to A's ROE of +0.20%. Regarding short-term risk, EXAS is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
EXAS vs IQV Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, IQV has a market cap of 42.5B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while IQV trades at $258.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas IQV's P/E ratio is 21.29. In terms of profitability, EXAS's ROE is -0.09%, compared to IQV's ROE of +0.22%. Regarding short-term risk, EXAS is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check IQV's competition here
Waters Corporation (NYSE: WAT)
EXAS vs WAT Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, WAT has a market cap of 41.7B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while WAT trades at $425.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas WAT's P/E ratio is 31.08. In terms of profitability, EXAS's ROE is -0.09%, compared to WAT's ROE of +0.02%. Regarding short-term risk, EXAS is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check WAT's competition here
Illumina, Inc. (NASDAQ: ILMN)
EXAS vs ILMN Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ILMN has a market cap of 41.3B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while ILMN trades at $273.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ILMN's P/E ratio is 54.28. In terms of profitability, EXAS's ROE is -0.09%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, EXAS is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check ILMN's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
EXAS vs IDXX Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, IDXX has a market cap of 40.9B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while IDXX trades at $518.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas IDXX's P/E ratio is 36.45. In terms of profitability, EXAS's ROE is -0.09%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, EXAS is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check IDXX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
EXAS vs MTD Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MTD has a market cap of 30B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while MTD trades at $1,486.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MTD's P/E ratio is 34.17. In terms of profitability, EXAS's ROE is -0.09%, compared to MTD's ROE of -12.00%. Regarding short-term risk, EXAS is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
EXAS vs DGX Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, DGX has a market cap of 25.7B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while DGX trades at $233.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas DGX's P/E ratio is 23.00. In terms of profitability, EXAS's ROE is -0.09%, compared to DGX's ROE of +0.14%. Regarding short-term risk, EXAS is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
EXAS vs LH Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, LH has a market cap of 25.3B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while LH trades at $308.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas LH's P/E ratio is 18.31. In terms of profitability, EXAS's ROE is -0.09%, compared to LH's ROE of +0.12%. Regarding short-term risk, EXAS is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
EXAS vs GH Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, GH has a market cap of 23.9B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while GH trades at $177.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas GH's P/E ratio is -50.95. In terms of profitability, EXAS's ROE is -0.09%, compared to GH's ROE of +2.11%. Regarding short-term risk, EXAS is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check GH's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
EXAS vs ILMNV Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ILMNV's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to ILMNV's ROE of N/A. Regarding short-term risk, EXAS is similarly volatile compared to ILMNV. This indicates similar risk in terms of short-term price fluctuations for EXAS.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
EXAS vs RVTY Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, RVTY has a market cap of 16.9B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while RVTY trades at $151.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas RVTY's P/E ratio is 28.30. In terms of profitability, EXAS's ROE is -0.09%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, EXAS is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check RVTY's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
EXAS vs MEDP Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MEDP has a market cap of 16.7B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while MEDP trades at $599.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MEDP's P/E ratio is 35.14. In terms of profitability, EXAS's ROE is -0.09%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, EXAS is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
EXAS vs PKI Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas PKI's P/E ratio is 41.45. In terms of profitability, EXAS's ROE is -0.09%, compared to PKI's ROE of +0.03%. Regarding short-term risk, EXAS is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
EXAS vs CRL Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CRL has a market cap of 14B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while CRL trades at $290.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CRL's P/E ratio is 29.31. In terms of profitability, EXAS's ROE is -0.09%, compared to CRL's ROE of -0.08%. Regarding short-term risk, EXAS is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
EXAS vs ICLR Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ICLR has a market cap of 12.4B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while ICLR trades at $162.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ICLR's P/E ratio is 13.22. In terms of profitability, EXAS's ROE is -0.09%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, EXAS is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
EXAS vs QGEN Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, QGEN has a market cap of 9.2B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while QGEN trades at $44.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas QGEN's P/E ratio is 18.49. In terms of profitability, EXAS's ROE is -0.09%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, EXAS is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
EXAS vs GRAL Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, GRAL has a market cap of 5.7B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while GRAL trades at $143.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas GRAL's P/E ratio is -13.60. In terms of profitability, EXAS's ROE is -0.09%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, EXAS is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
EXAS vs RDNT Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while RDNT trades at $69.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas RDNT's P/E ratio is 152.02. In terms of profitability, EXAS's ROE is -0.09%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, EXAS is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
EXAS vs SHC Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while SHC trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas SHC's P/E ratio is 18.98. In terms of profitability, EXAS's ROE is -0.09%, compared to SHC's ROE of +0.27%. Regarding short-term risk, EXAS is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
EXAS vs BLLN Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BLLN has a market cap of 4.9B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while BLLN trades at $105.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BLLN's P/E ratio is 151.29. In terms of profitability, EXAS's ROE is -0.09%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, EXAS is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
EXAS vs SYNH Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas SYNH's P/E ratio is 61.40. In terms of profitability, EXAS's ROE is -0.09%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, EXAS is less volatile compared to SYNH. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
EXAS vs VCYT Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while VCYT trades at $45.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas VCYT's P/E ratio is 22.91. In terms of profitability, EXAS's ROE is -0.09%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, EXAS is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
EXAS vs CDNA Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CDNA has a market cap of 3.5B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while CDNA trades at $67.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CDNA's P/E ratio is 79.94. In terms of profitability, EXAS's ROE is -0.09%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, EXAS is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
EXAS vs OLK Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas OLK's P/E ratio is -96.59. In terms of profitability, EXAS's ROE is -0.09%, compared to OLK's ROE of -0.07%. Regarding short-term risk, EXAS is less volatile compared to OLK. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
EXAS vs WGS Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, WGS has a market cap of 2.2B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while WGS trades at $73.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas WGS's P/E ratio is 203.03. In terms of profitability, EXAS's ROE is -0.09%, compared to WGS's ROE of -0.39%. Regarding short-term risk, EXAS is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
EXAS vs PSNL Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while PSNL trades at $16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas PSNL's P/E ratio is -14.94. In terms of profitability, EXAS's ROE is -0.09%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, EXAS is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
EXAS vs OPK Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while OPK trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas OPK's P/E ratio is -5.78. In terms of profitability, EXAS's ROE is -0.09%, compared to OPK's ROE of -0.06%. Regarding short-term risk, EXAS is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
EXAS vs CSTL Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while CSTL trades at $35.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CSTL's P/E ratio is -53.88. In terms of profitability, EXAS's ROE is -0.09%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, EXAS is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
EXAS vs FLGT Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, FLGT has a market cap of 610M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while FLGT trades at $21.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas FLGT's P/E ratio is 2148.00. In terms of profitability, EXAS's ROE is -0.09%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, EXAS is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
EXAS vs GRALV Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas GRALV's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to GRALV's ROE of N/A. Regarding short-term risk, EXAS is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
EXAS vs NEO Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NEO has a market cap of 474.6M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while NEO trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NEO's P/E ratio is 142.08. In terms of profitability, EXAS's ROE is -0.09%, compared to NEO's ROE of -0.06%. Regarding short-term risk, EXAS is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
EXAS vs MYGN Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MYGN has a market cap of 428.8M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while MYGN trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MYGN's P/E ratio is -34.92. In terms of profitability, EXAS's ROE is -0.09%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, EXAS is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
EXAS vs CO Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CO's P/E ratio is 5.06. In terms of profitability, EXAS's ROE is -0.09%, compared to CO's ROE of +0.11%. Regarding short-term risk, EXAS is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
EXAS vs FLDM Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas FLDM's P/E ratio is -4.74. In terms of profitability, EXAS's ROE is -0.09%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, EXAS is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
EXAS vs BDSX Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BDSX has a market cap of 225.6M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while BDSX trades at $27.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BDSX's P/E ratio is -8.74. In terms of profitability, EXAS's ROE is -0.09%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, EXAS is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
EXAS vs XGN Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, XGN has a market cap of 197.4M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while XGN trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas XGN's P/E ratio is -10.09. In terms of profitability, EXAS's ROE is -0.09%, compared to XGN's ROE of -1.22%. Regarding short-term risk, EXAS is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
EXAS vs FRNM Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, FRNM has a market cap of 133.1M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while FRNM trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas FRNM's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to FRNM's ROE of N/A. Regarding short-term risk, EXAS is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
EXAS vs GTH Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas GTH's P/E ratio is -1.11. In terms of profitability, EXAS's ROE is -0.09%, compared to GTH's ROE of -1.01%. Regarding short-term risk, EXAS is less volatile compared to GTH. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
EXAS vs GENE Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas GENE's P/E ratio is -38.25. In terms of profitability, EXAS's ROE is -0.09%, compared to GENE's ROE of -1.85%. Regarding short-term risk, EXAS is similarly volatile compared to GENE. This indicates similar risk in terms of short-term price fluctuations for EXAS.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
EXAS vs IMDX Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, IMDX has a market cap of 111.1M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while IMDX trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas IMDX's P/E ratio is -2.31. In terms of profitability, EXAS's ROE is -0.09%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, EXAS is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
EXAS vs SERA Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, SERA has a market cap of 79.1M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while SERA trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas SERA's P/E ratio is -3.18. In terms of profitability, EXAS's ROE is -0.09%, compared to SERA's ROE of -0.47%. Regarding short-term risk, EXAS is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
EXAS vs PRPO Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, PRPO has a market cap of 41.3M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while PRPO trades at $23.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas PRPO's P/E ratio is -35.58. In terms of profitability, EXAS's ROE is -0.09%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, EXAS is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
EXAS vs QUCY Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, QUCY has a market cap of 30.5M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while QUCY trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas QUCY's P/E ratio is -0.06. In terms of profitability, EXAS's ROE is -0.09%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, EXAS is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
EXAS vs MDXH Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MDXH has a market cap of 29.3M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while MDXH trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MDXH's P/E ratio is -0.78. In terms of profitability, EXAS's ROE is -0.09%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, EXAS is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
EXAS vs AKU Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas AKU's P/E ratio is -0.13. In terms of profitability, EXAS's ROE is -0.09%, compared to AKU's ROE of -5.32%. Regarding short-term risk, EXAS is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
EXAS vs BNR Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BNR has a market cap of 17.3M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while BNR trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BNR's P/E ratio is -18.84. In terms of profitability, EXAS's ROE is -0.09%, compared to BNR's ROE of -0.13%. Regarding short-term risk, EXAS is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
EXAS vs CEMI Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CEMI's P/E ratio is -0.63. In terms of profitability, EXAS's ROE is -0.09%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, EXAS is similarly volatile compared to CEMI. This indicates similar risk in terms of short-term price fluctuations for EXAS.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
EXAS vs ENZ Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ENZ's P/E ratio is -2.24. In terms of profitability, EXAS's ROE is -0.09%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, EXAS is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
EXAS vs PMD Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas PMD's P/E ratio is -5.24. In terms of profitability, EXAS's ROE is -0.09%, compared to PMD's ROE of -0.32%. Regarding short-term risk, EXAS is similarly volatile compared to PMD. This indicates similar risk in terms of short-term price fluctuations for EXAS.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
EXAS vs ME Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ME's P/E ratio is -0.03. In terms of profitability, EXAS's ROE is -0.09%, compared to ME's ROE of -42.03%. Regarding short-term risk, EXAS is similarly volatile compared to ME. This indicates similar risk in terms of short-term price fluctuations for EXAS.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
EXAS vs MYNZ Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, EXAS's ROE is -0.09%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, EXAS is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check MYNZ's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
EXAS vs BIAFW Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BIAFW has a market cap of 11.8M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while BIAFW trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BIAFW's P/E ratio is 1.25. In terms of profitability, EXAS's ROE is -0.09%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, EXAS is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check BIAFW's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
EXAS vs CHEK Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CHEK's P/E ratio is -0.43. In terms of profitability, EXAS's ROE is -0.09%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, EXAS is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
EXAS vs CNTG Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CNTG's P/E ratio is -0.23. In terms of profitability, EXAS's ROE is -0.09%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, EXAS is similarly volatile compared to CNTG. This indicates similar risk in terms of short-term price fluctuations for EXAS.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
EXAS vs ADVB Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ADVB has a market cap of 9.3M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while ADVB trades at $6.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ADVB's P/E ratio is -61.00. In terms of profitability, EXAS's ROE is -0.09%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, EXAS is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
EXAS vs NDRA Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while NDRA trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NDRA's P/E ratio is -0.90. In terms of profitability, EXAS's ROE is -0.09%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, EXAS is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
EXAS vs APDN Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas APDN's P/E ratio is -0.10. In terms of profitability, EXAS's ROE is -0.09%, compared to APDN's ROE of -7.23%. Regarding short-term risk, EXAS is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
EXAS vs NVTA Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NVTA's P/E ratio is -0.00. In terms of profitability, EXAS's ROE is -0.09%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, EXAS is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
EXAS vs LMDX Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas LMDX's P/E ratio is -0.01. In terms of profitability, EXAS's ROE is -0.09%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, EXAS is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
EXAS vs LMDXW Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, EXAS's ROE is -0.09%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, EXAS is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check LMDXW's competition here
DermTech, Inc. (NASDAQ: DMTK)
EXAS vs DMTK Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas DMTK's P/E ratio is -0.04. In terms of profitability, EXAS's ROE is -0.09%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, EXAS is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
EXAS vs NOTV Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NOTV's P/E ratio is -0.03. In terms of profitability, EXAS's ROE is -0.09%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, EXAS is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check NOTV's competition here
iSpecimen Inc. (NASDAQ: ISPC)
EXAS vs ISPC Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, ISPC has a market cap of 2.6M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while ISPC trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas ISPC's P/E ratio is -0.03. In terms of profitability, EXAS's ROE is -0.09%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, EXAS is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
EXAS vs BIAF Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BIAF has a market cap of 2.5M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while BIAF trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BIAF's P/E ratio is -0.71. In terms of profitability, EXAS's ROE is -0.09%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, EXAS is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
EXAS vs SQL Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas SQL's P/E ratio is -0.40. In terms of profitability, EXAS's ROE is -0.09%, compared to SQL's ROE of -30.46%. Regarding short-term risk, EXAS is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
EXAS vs AWH Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas AWH's P/E ratio is -0.09. In terms of profitability, EXAS's ROE is -0.09%, compared to AWH's ROE of +1.62%. Regarding short-term risk, EXAS is similarly volatile compared to AWH. This indicates similar risk in terms of short-term price fluctuations for EXAS.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
EXAS vs HTGM Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas HTGM's P/E ratio is -0.03. In terms of profitability, EXAS's ROE is -0.09%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, EXAS is similarly volatile compared to HTGM. This indicates similar risk in terms of short-term price fluctuations for EXAS.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
EXAS vs BIOC Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BIOC's P/E ratio is -0.01. In terms of profitability, EXAS's ROE is -0.09%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, EXAS is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
EXAS vs SQLLW Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, EXAS's ROE is -0.09%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, EXAS is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
EXAS vs WGSWW Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, EXAS's ROE is -0.09%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, EXAS is similarly volatile compared to WGSWW. This indicates similar risk in terms of short-term price fluctuations for EXAS.Check WGSWW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
EXAS vs BNGOW Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas BNGOW's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, EXAS is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check BNGOW's competition here
Danaher Corporation (NYSE: DHR-PA)
EXAS vs DHR-PA Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, EXAS's ROE is -0.09%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, EXAS is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check DHR-PA's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
EXAS vs OCDX Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas OCDX's P/E ratio is -42.28. In terms of profitability, EXAS's ROE is -0.09%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, EXAS is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check OCDX's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
EXAS vs CHEKZ Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, EXAS is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check CHEKZ's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
EXAS vs NDRAW Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas NDRAW's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, EXAS is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check NDRAW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
EXAS vs PRXL Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas PRXL's P/E ratio is 42.97. In terms of profitability, EXAS's ROE is -0.09%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, EXAS is less volatile compared to PRXL. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check PRXL's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
EXAS vs MEUSW Comparison October 2026
Exact Sciences Corporation (NASDAQ: EXAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 20B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, EXAS is priced at $104.91 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -95.37, whereas MEUSW's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.09%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, EXAS is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for EXAS.Check MEUSW's competition here